Press Releases | Gilead - Gilead Sciences
WEBJul 25, 2024 · Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024. January 22, 2024. Gilead Provides Update on Phase 3 EVOKE-01 Study. Read the latest news about Gilead's work in COVID-19, HIV, viral hepatitis, cancer and other areas.
Newsroom | Gilead - Gilead Sciences
WEBRecent Press Releases. September 12, 2024. Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial. September 10, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
WEBFeb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
News Details - Gilead Sciences
WEBJun 20, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in ...
Gilead Lenacapavir cut HIV infections by 96% in trial - CNBC
WEBSep 12, 2024 · A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday ...
Gilead’s Innovative HIV Treatment Research Pipeline ... - Gilead Sciences
WEBMar 5, 2024 · In a recent Phase 1b study published in The Lancet HIV, the investigational combination of lenacapavir + teropavimab (GS-5423, TAB) + zinlirvimab (GS-2872, ZAB) demonstrated high efficacy and maintained virologic …
Gilead Sciences Announces Completion of Acquisition of CymaBay
WEBFOSTER CITY, Calif., March 22, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq:...
Gilead's breast cancer drug gets U.S. FDA approval for third …
WEBFeb 3 (Reuters) - Gilead Sciences (GILD.O) said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option...
News Details - Gilead Sciences
WEBFeb 2, 2023 · Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results. February 2, 2023. Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022. Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022. Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022.
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History
WEBFind the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Skip to content